Levorichter 30 (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol provides estrogenic activity that stabilizes the endometrial lining, while levonorgestrel acts as a progestogen to suppress the luteinizing hormone surge, preventing ovulation. Together they thicken cervical mucus and alter the uterine lining, creating an environment that hinders fertilization and implantation.

The dosing regimen for Levorichter 30 is determined by the prescribing healthcare professional. Typically, it is taken once daily at the same time for a 21‑day active phase followed by a 7‑day hormone‑free interval, but exact instructions must follow the prescriber’s order.

Levorichter 30 is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it may cause fetal harm. It is also not recommended while breastfeeding, as hormonal components can be excreted in breast milk and may affect the infant.

To order Levorichter 30, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levorichter 30 contains a standard dose of ethinylestradiol combined with levonorgestrel, a widely used progestogen. Compared with pills that use newer progestins, it offers a well‑characterized safety profile and efficacy. Choice among COCs often depends on individual risk factors, tolerability, and clinician preference.

Levorichter 30 tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Levorichter 30 is taken orally with water, preferably at the same time each day. The typical regimen involves 21 consecutive active tablets followed by a 7‑day hormone‑free interval, during which withdrawal bleeding occurs. Patients should follow the specific instructions provided by their prescriber.

The most serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, and severe allergic reactions. These events are rare but can be life‑threatening, especially in women with pre‑existing cardiovascular risk factors, smoking habits, or a history of clotting disorders.

Levorichter 30 is contraindicated in women who are pregnant, have a known or suspected estrogen‑dependent tumor, have a history of thromboembolic disease, severe liver disease, uncontrolled hypertension, or are smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.